Ignite Creation Date:
2024-05-05 @ 6:42 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00538694
Status:
COMPLETED
Last Update Posted:
2019-11-14
First Post:
2007-10-01
Brief Title:
Comparative Study of Cidecin Daptomycin to Rocephin Ceftriaxone in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Study Overview
Official Title:
A Randomized Double-Blind Phase III Comparative Study of Cidecin Daptomycin to Rocephin Ceftriaxone in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S Pneumoniae
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None